Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease
Authors:
- P.D MehtaPMP.D Mehta
- T PirttilaTPT Pirttila
- B.A PatrickBPB.A Patrick
- M BarshatzkyMBM Barshatzky
- S.P MehtaSMS.P Mehta
- 1 May 2001
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 304 (1-2) , 102-106
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloidProceedings of the National Academy of Sciences, 1999
- Plasma amyloid ?-peptide 1-42 and incipient Alzheimer's diseaseAnnals of Neurology, 1999
- High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E GenotypeArchives of Neurology, 1998
- Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral ArteriesJournal of Neurochemistry, 1996
- Platelets Are the Primary Source of Amyloid β-Peptide in Human BloodBiochemical and Biophysical Research Communications, 1995
- Amyloid β Protein (Aβ) in Alzheimeri's Disease BrainJournal of Biological Chemistry, 1995
- Passage of human amyloid β-protein 1–40 across the murine blood-brain barrierLife Sciences, 1994
- α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementiaAnnals of Neurology, 1990
- Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer's diseaseCell, 1988
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984